ENDRA Life Sciences Inc. (Nasdaq: NDRA) has announced a strategic shift aimed at maximizing shareholder value, which includes a reduction in its workforce. On March 19, 2026, the company reduced its employee count to decrease cash expenditures and extend its operational runway. This decision is expected to incur pre-tax cash charges of approximately $51,000 related to severance payments for former employees. While the company continues to pursue its TAEUS business, this move reflects a significant change in its strategic direction. The company has engaged Lucid Capital Management as its financial advisor and K&L Gates as its legal counsel to explore various strategic alternatives, including potential mergers, business combinations, or asset sales. The board of directors is committed to evaluating these options while maintaining focus on core business priorities. ENDRA has not set a specific timetable for the completion of this review process and will provide updates as necessary. The company aims to navigate through these changes while continuing to execute its strategic and operational initiatives.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.